{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal placental",
            "NStudiesAvail": 430108,
            "NStudiesFound": 26,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 26,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Xiuli Zhao, Doc"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The rate of adverse event in 24 hours after single dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer.",
                              "The rate of adverse event in 7 days after multi-dose of Human placental mesenchymal stem cells gel on Human diabetic food ulcer."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Rate of adverse event",
                              "Rate of adverse event"
                        ],
                        "NCTId": [
                              "NCT04464213"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "chengyun zheng, Ph. D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To assess efficacy of MSC through comparing the change of ITT, Hemoglobin A1c, FBG, PBG, C-peptide levels and T cell subsets with that of baseline.\n\nThe change of insulin resistance index(ITT) compared with baseline.\nRate of reducing exogenous insulin requirement compared with baseline.\nThe change of Fast blood glucose (FBG) and Postmeal blood glucose (PBG) compared with baseline.\nA reduction of \u22651% in HbA1c compared with baseline.\nThe change of C-peptide levels compared with baseline.\nThe change of T cell subsets compared with baseline."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To assess efficacy of transplantation treatment using umbilical cord/placenta-derived mesenchymal stem cells in patients with type 2 diabetes mellitus"
                        ],
                        "NCTId": [
                              "NCT01413035"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "assessing the adverse outcomes after an injection such as acute allergic reactions, systemic effects such as fever, tachycardia, nausea and vomiting, diarrhea, cardinal manifestations, neutropenia, leukopenia, hemolysis, and local reactions such as cellulitis, abscess, skin rash, bleeding, necrosis",
                              "They are assessing the clinical response to therapy which might demonstrate the closure of refractory fistulas. These results include a full fistula closure in clinical observation and radiological assessments by MRI. Clinical improvement can be described as improvements in clinical manifestations such as pain, discharge, and bloody discharges. The fistulae are also assessed with MRI scans.",
                              "assessing inflammatory markers through laboratory workup, including CRP, IL-6, TNF-a, calprotectin"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of injected exosomes",
                              "clinical Efficacy of injected exosomes",
                              "inflammatory markers"
                        ],
                        "NCTId": [
                              "NCT05499156"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Daniel Chambers, MBBS MRCP FRACP MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [
                              "daniel.chambers@health.qld.gov.au"
                        ],
                        "PointOfContactOrganization": [
                              "The Prince Chalres Hospital"
                        ],
                        "PointOfContactPhone": [
                              "+61 7 3139 4000"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Assoc Professor Daniel Chambers"
                        ],
                        "PrimaryCompletionDate": [
                              "May 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Acute adverse events following infusion was defined as the development of anaphalaxis and/or a 25% increase or decrease from baseline of hemodynamic measurements."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of Participants Who Demonstrated Acute Adverse Events Following Infusion"
                        ],
                        "NCTId": [
                              "NCT01385644"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 22, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "assessing the adverse outcomes after injection such as acute allergic reactions",
                              "assessing the clinical response to therapy which might demonstrate itself as closure of refractory fistulas",
                              "assessing inflammatory markers through laboratory workup including CRP, IL-6, TNF-a, calprotectin."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of injected exosomes",
                              "clinical Efficacy of injected exosomes",
                              "inflammatory markers"
                        ],
                        "NCTId": [
                              "NCT05402748"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Michael P. Zahalsky, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)"
                        ],
                        "NCTId": [
                              "NCT02395029"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Michael P. Zahalsky, M.D."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)",
                              "Peak Systolic Velocity without trimix (cm/s)"
                        ],
                        "NCTId": [
                              "NCT02398370"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Peter Nemtinov, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Treatment-related adverse events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse events and changes in physical examinations, vital signs and the results of clinical lab tests."
                        ],
                        "NCTId": [
                              "NCT04453111"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Diana L Farmer, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Will be assessed by evaluating the presence or absence of cerebrospinal fluid leak, infection at the MMC repair site, failure of the MMC repair site to heal, and any unexpected growths or tumor formation. These will be assessed at birth by physical exam, brain and spinal ultrasound , and brain and spinal MRI."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety of the placenta-derived mesenchymal stem cell (PMSC-ECM) Product"
                        ],
                        "NCTId": [
                              "NCT04652908"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "chengyun zheng, Ph. D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an abosolute change\u22651 units on a 0-10 scale(0=no disease activity;10=high disease activity)for \u22653 domains,and no worsening in remaining domain.\n\nPatient global Pain Function (as measured by the Bath Ankylosing Spondylitis Functional Index - BASFI) Inflammation (mean of the Bath Ankylosing Spondylitis Disease Activity Index - BASDAI question 5 and 6)",
                              "erythrocyte sedimentation rate (ESR) level will be mainly observed after transplanting 3, 6,12-month.",
                              "imageology will be mainly observed after transplanting 3, 6,12-month.",
                              "C-reactive protein (CRP) level will be mainly observed after transplanting 3, 6,12-month."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The Assessment of Spondyloarthritis International Society (ASAS)20 response",
                              "erythrocyte sedimentation rate (ESR)",
                              "imageology",
                              "C-reactive protein (CRP)"
                        ],
                        "NCTId": [
                              "NCT01420432"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "chengyun zheng, Ph. D"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Anemia symptoms, bleeding and infection will be mainly observed in every monthly after transplanting MSCs for one year.",
                              "The number of blood cells, which contains WBC, Neu, RBC, Hb,PLT and reticulocyte, will be mainly tested monthly after transplantion of MSCs for one year",
                              "Bone borrow cytomorphologic examination will be tested in every 3 months after transplantion of MSCs for one year."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "SAA clinical symptoms",
                              "The number of blood cells",
                              "Bone borrow hemocytology"
                        ],
                        "NCTId": [
                              "NCT01182662"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "cheng yun zheng, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Anemia symptoms will be mainly observed in every week after transplanting MSCs for one year.",
                              "A routine blood test, which contains WBC, Neu, RBC, Hb and PLT, will be mainly tested in every month after transplanting MSCs for one year.",
                              "Bone borrow cytomorphologic examination will be tested in every 3 months after transplanting MSCs for one year."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "MDS clinical symptoms (mainly anemia symptoms)",
                              "A routine blood test",
                              "Bone borrow cytomorphologic examination"
                        ],
                        "NCTId": [
                              "NCT01129739"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "YU TANG, Dr."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of participants with adverse events as measure of safety and tolerability"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "adverse events"
                        ],
                        "NCTId": [
                              "NCT03028428"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluate incidences of Treatment-Emergent Adverse Events following EV-Pure\u2122 and WJ-Pure\u2122 administeration in patients exhibiting moderate to severe ARDS associated with COVID-19 compared to placebo. Presence of adverse events in less than 10% of the study population, as a measure of safety",
                              "Clinical data will be evaluated to determine if there were any significant changes in the COVID-19 symptoms in patients in the treated versus placebo groups. The following information will be collected to evaluate the effectiveness of the treatment at 4 weeks post- treatment:\n\nDischarged home on no supplemental oxygen\nDischarged home on supplemental oxygen\nContinued hospitalization on no oxygen\nContinued hospitalization on oxygen but not in ICU\nContinued hospitalization on oxygen in ICU (invasive and noninvasive ventilatory support)\nDeath"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To Assess the safety of EV-Pure\u2122 and WJ-Pure\u2122 administration in patients exhibiting moderate to severe ARDS associated with COVID-19, compared to placebo.",
                              "To assess the efficacy of EV-Pure\u2122 and WJ-Pure\u2122 compared to placebo, in patients with moderate to severe ARDS assoociated with COVID-19"
                        ],
                        "NCTId": [
                              "NCT05387278"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Peter Nemtinov, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Improvement of pulmonary function. Arterial oxygen tension PaO2 (in mmHg)/fractional inspired oxygen FiO2 (expressed as a fraction, not a percentage), most conveniently the P/F ratio. The normal P/F ratio is ~ 400-500 mmHg (~55-65 kPa). P/F ratio <300mmHg - sign of Acute Respiratory Distress Syndrome (ARDS)",
                              "Length of Hospital Stay",
                              "Marker for efficacy of treatment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes of oxygenation index PaO2/FiO2, most conveniently the P/F ratio.",
                              "Changes in length of hospital stay",
                              "Changes in mortality rate"
                        ],
                        "NCTId": [
                              "NCT04461925"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Leanne M Redman, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 11, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Infant in vitro mitochondrial capacity measured by oxygen consumption rates in umbilical cord derived mesenchymal stem cells at delivery"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Infant in vitro mitochondrial capacity (by oxygen consumption rate)"
                        ],
                        "NCTId": [
                              "NCT03489564"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 26, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will perform as many sit-to-stand movements as they can in 30 seconds and then will rate pain",
                              "Participants will perform a supine to upright movement as quickly as they can and then will rate pain",
                              "Participants will ascend and decent 10 stairs as quickly as they can and then will rate pain"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months",
                              "Change in pain during sit-to-stand over 3 months",
                              "Change in pain during supine to upright over 3 months",
                              "Change in pain during ascent/decent stairs over 3 months"
                        ],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Prof. Carsten Tsch\u00f6pe, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events, Safety laboratory values and ECG findings",
                              "Immunological reaction"
                        ],
                        "NCTId": [
                              "NCT00919958"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Prof. Igor B Resnick, MD, PhD, DSci"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "GVHD re-staging and/or GVHD mortality ,side effects"
                        ],
                        "NCTId": [
                              "NCT00749164"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Adverse events; Amputation incidence, Death incidence & Rehospitalization incidence",
                              "Immunological reaction"
                        ],
                        "NCTId": [
                              "NCT00951210"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 4, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of ventilator-free days"
                        ],
                        "NCTId": [
                              "NCT04614025"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Daniel Chambers, MRCP FRACP MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of treatment-emergent AEs (frequency and severity at each dose level)",
                              "Incidence of SAEs"
                        ],
                        "NCTId": [
                              "NCT01795950"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 17, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Number of ventilator free days"
                        ],
                        "NCTId": [
                              "NCT04389450"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "Michael Cotten, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 28, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "for this study, infusion reactions are defined as anaphylactic or anaphylactoid reactions with clinical signs inclusive of skin rashes, bronchospasm, angioedema, myocardial infarcts, arrhythmias, and acute lung injury.",
                              "for this study, infections recorded as safety endpoints will be defined as bacterial, viral or fungal infections identified by culture or molecular methodologies within two weeks after administration of hCT-MSC."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of infusion reactions",
                              "Incidence of Infections post-infusion"
                        ],
                        "NCTId": [
                              "NCT03635450"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Leanne M Redman, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 8, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Assessed during a mixed-meal test as the difference in RQ between the postprandial period and the fasting period via indirect calorimetry."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Metabolic flexibility - Mother"
                        ],
                        "NCTId": [
                              "NCT02926079"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [
                              "Nawara Mohamed Hashish, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2015"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Comparison of the implantation rates of all groups; the differentiated stem cell group, the undifferentiated stem cell group and the control group to assess the efficacy of differentiated and undifferentiated stem cell therapy in improving endometrial receptivity."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Implantation rate"
                        ],
                        "NCTId": [
                              "NCT01649752"
                        ]
                  }
            ]
      }
}